TELO

Telomir is a preclinical-stage shell wrapped around a single in-licensed molecule. By its own 10-K it is 'a preclinical-stage pharmaceutical company' whose 'business currently depends entirely on the successful development, regulatory approval, and licensing or commercialization of our product candidate, which may never occur.' Telomir-1 has not entered the clinic — the merger conditions reference funding tied to *future* 'FDA acceptance of an IND' and 'initiation of a Phase 1/2 study,' meaning there is no IND yet, no human data, and years of cash-burning work before any value-inflection. There is no revenue in any year on record (FY2022–FY2025 all blank), only cumulative losses building a -$41.0M accumulated deficit. This is the most speculative end of the risk spectrum, and the filing says so explicitly: 'Investing in shares of our common stock is very speculative and involves a high degree of risk... you could lose part or all of your investment.'

The single most damaging fact is that the company does not own its core asset. Telomir-1 is in-licensed from MIRALOGX, and 'We do not currently own any intellectual property rights, including the patent application that underlies this license.' Management concedes it had no control over drafting or prosecution of the patent, that 'patent protection for naturally occurring compounds is exceedingly difficult to obtain, defend and enforce,' and that royalty non-payment, confidentiality breaches, or licensor litigation could trigger 'loss of the license and inability to continue operations.' A drug company that can lose its only drug to a third party is structurally fragile. The pending TELI merger is framed as consolidating worldwide rights to Telomir-1, but the consideration shares 'will not be registered,' and the deal layers integration and ownership-structure risk on top of the science risk.